Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71


Incorporation of innate immune effector mechanisms in the formulation of a vaccine against HIV-1.

Ansari AA, Mayne AE, Takahashi Y, Pattanapanyasat K.

Adv Exp Med Biol. 2011;780:143-59. doi: 10.1007/978-1-4419-5632-3_12. Review.


Inflammation and gut permeability.

Byakwaga H, Boesecke C, Emery S.

J HIV Ther. 2009 Nov;14(3):57-60. Review. No abstract available.


KIRigami: the case for studying NK cell receptors in SIV+ macaques.

Bimber B, O'Connor DH.

Immunol Res. 2008;40(3):235-43. Review.


Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses.

Abel K, Pahar B, Van Rompay KK, Fritts L, Sin C, Schmidt K, Colón R, McChesney M, Marthas ML.

J Virol. 2006 Jul;80(13):6357-67.


The primate connection.

Trivedi B.

Nature. 2010 Jul 15;466(7304):S5. doi: 10.1038/nature09236. No abstract available.


Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL.

Science. 2000 Oct 20;290(5491):486-92.


Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection.

Reeves RK, Rajakumar PA, Evans TI, Connole M, Gillis J, Wong FE, Kuzmichev YV, Carville A, Johnson RP.

Blood. 2011 Sep 22;118(12):3321-30. doi: 10.1182/blood-2011-04-347260. Epub 2011 Jul 26.


Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, Shiver JW, Robert-Guroff M, Robertson MN, McChesney MB, Gilbert PB, Miller CJ.

J Virol. 2012 Feb;86(4):2239-50. doi: 10.1128/JVI.06175-11. Epub 2011 Dec 7.


Impact of vaccination on cytotoxic T lymphocyte immunodominance and cooperation against simian immunodeficiency virus replication in rhesus macaques.

Ishii H, Kawada M, Tsukamoto T, Yamamoto H, Matsuoka S, Shiino T, Takeda A, Inoue M, Iida A, Hara H, Shu T, Hasegawa M, Naruse TK, Kimura A, Takiguchi M, Matano T.

J Virol. 2012 Jan;86(2):738-45. doi: 10.1128/JVI.06226-11. Epub 2011 Nov 9.


SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.

Cafaro A, Caputo A, Maggiorella MT, Baroncelli S, Fracasso C, Pace M, Borsetti A, Sernicola L, Negri DR, Ten Haaft P, Betti M, Michelini Z, Macchia I, Fanales-Belasio E, Belli R, Corrias F, Buttò S, Verani P, Titti F, Ensoli B.

J Med Primatol. 2000 Aug;29(3-4):193-208.


Live-attenuated lentivirus immunization modulates innate immunity and inflammation while protecting rhesus macaques from vaginal simian immunodeficiency virus challenge.

Genescà M, Ma ZM, Wang Y, Assaf B, Qureshi H, Fritts L, Huang Y, McChesney MB, Miller CJ.

J Virol. 2012 Sep;86(17):9188-200. doi: 10.1128/JVI.00532-12. Epub 2012 Jun 13.


ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.

Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC, Miller NR, Tryniszewska E, Lewis MG, VanCott TC, Hirsch V, Woodward R, Gibson A, Grace M, Dobratz E, Markham PD, Hel Z, Nacsa J, Klein M, Tartaglia J, Franchini G.

J Virol. 2002 Jan;76(1):292-302.


Vaccine-based, long-term, stable control of simian/human immunodeficiency virus 89.6PD replication in rhesus macaques.

Yamamoto H, Kawada M, Tsukamoto T, Takeda A, Igarashi H, Miyazawa M, Naruse T, Yasunami M, Kimura A, Matano T.

J Gen Virol. 2007 Feb;88(Pt 2):652-9.


Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.

Allen TM, Mortara L, Mothé BR, Liebl M, Jing P, Calore B, Piekarczyk M, Ruddersdorf R, O'Connor DH, Wang X, Wang C, Allison DB, Altman JD, Sette A, Desrosiers RC, Sutter G, Watkins DI.

J Virol. 2002 Apr;76(8):4108-12.


Innate immune cell responses in non pathogenic versus pathogenic SIV infections.

Huot N, Rascle P, Garcia-Tellez T, Jacquelin B, Müller-Trutwin M.

Curr Opin Virol. 2016 Aug;19:37-44. doi: 10.1016/j.coviro.2016.06.011. Epub 2016 Jul 20. Review.


Association of activating KIR copy number variation of NK cells with containment of SIV replication in rhesus monkeys.

Hellmann I, Lim SY, Gelman RS, Letvin NL.

PLoS Pathog. 2011 Dec;7(12):e1002436. doi: 10.1371/journal.ppat.1002436. Epub 2011 Dec 15. Erratum in: PLoS Pathog. 2012 Sep;8(9). doi:10.1371/annotation/03a74287-7d68-483d-858b-ae8f3b3df54a.


Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.

Mooij P, Nieuwenhuis IG, Knoop CJ, Doms RW, Bogers WM, Ten Haaft PJ, Niphuis H, Koornstra W, Bieler K, Köstler J, Morein B, Cafaro A, Ensoli B, Wagner R, Heeney JL.

J Virol. 2004 Apr;78(7):3333-42.


KIR/HLA: genetic clues for a role of NK cells in the control of HIV.

Fadda L, Alter G.

Adv Exp Med Biol. 2011;780:27-36. doi: 10.1007/978-1-4419-5632-3_3. Review.


Supplemental Content

Support Center